keyword
MENU ▼
Read by QxMD icon Read
search

Lamivudine

keyword
https://www.readbyqxmd.com/read/28107377/hbeag-seroconversion-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-long-term-nucleos-t-ide-analog-treatment-a-systematic-review-and-network-meta-analysis
#1
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye
BACKGROUND: HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. METHODS: Network meta-analysis of NA treatment-induced HBeAg seroconversion after 1-2 years of treatment was performed. In addition, NA treatment-induced HBeAg seroconversion after 3-5 years of treatment was systematically evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28102412/organobase-catalyzed-1-2-brook-rearrangement-of-silyl-glyoxylates
#2
Man-Yi Han, Fei-Yan Yang, Di Zhou, Zhigang Xu
A highly efficient [1,2]-Brook rearrangement of silyl glyoxylates has been developed using DBU as the organobase-catalyst. This [1,2]-Brook rearrangement is applicable to a number of thiols and secondary phosphine oxides containing acidic protons. These nucleophiles afford the corresponding Brook products in high yields. Using this methodology, a formal synthesis of anti-HIV drug compound lamivudine was realized.
January 19, 2017: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/28099188/hepatitis-b-incidence-and-prevention-with-antiretroviral-therapy-among-hiv-positive-individuals-in-rakai-uganda
#3
Emmanuel Seremba, Victor Ssempijja, Sarah Kalibbala, Ronald H Gray, Maria J Wawer, Fred Nalugoda, Corey Casper, Warren T Phipps, Ponsiano Ocama, David Serwadda, David L Thomas, Steven Reynolds
OBJECTIVE: Antiretroviral therapy (ART) may interfere with replication of hepatitis B (HBV) raising the hypothesis that HBV infection might be prevented by ART. We investigated the incidence and risk factors associated with HBV among HIV-infected adults in Rakai, Uganda. METHODS: We screened stored sera from 944 HIV-infected adults enrolled in the Rakai Community Cohort Study between September 2003 and March 2015 for evidence of HBV exposure. Serum from participants who tested anti-HBc negative (497) at baseline were tested over 3-7 consecutive survey rounds for incident HBV...
January 17, 2017: AIDS
https://www.readbyqxmd.com/read/28093483/treatment-simplification-to-atazanavir-ritonavir%C3%A2-%C3%A2-lamivudine-versus-maintenance-of-atazanavir-ritonavir%C3%A2-%C3%A2-two-nrtis-in-virologically-suppressed-hiv-1-infected-patients-48-week-results-from-a-randomized-trial-atlas-m
#4
Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, Alessandra Latini, Gabriella D'Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Massimo Di Pietro, Annalisa Mondi, Nicoletta Ciccarelli, Alberto Borghetti, Emanuele Focà, Manuela Colafigli, Andrea De Luca, Roberto Cauda
BACKGROUND: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir  +  lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. METHODS: We performed an open-label, multicentre, randomized, non-inferiority study, enrolling HIV-infected adults on atazanavir/ritonavir + two NRTIs, with stable HIV-RNA <50 copies/mL and CD4 + >200 cells/mm(3) Main exclusion criteria were hepatitis B virus coinfection, past virological failure on or resistance to study drugs, recent AIDS and pregnancy...
January 15, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28088502/the-nucleotide-changes-within-hbv-core-promoter-precore-during-the-first-12weeks-of-nucleos-t-ide-treatment-might-be-associated-with-a-better-virological-response
#5
Yaqin Peng, Yutang Li, Jinlin Hou, Jian Sun, Mingze Su, Yao Li, Kuanhui Xiang, Ling Yan, Hui Zhuang, Tong Li
OBJECTIVES: We aimed to study the dynamic changes of hepatitis B virus (HBV) core promoter/precore (CP/preC) sequences during antiviral treatment and their associations with virological responses. MATERIALS AND METHODS: The baseline and 12-week CP/preC sequences (nts 1655-2014) were obtained from 52 chronic hepatitis B patients with positive hepatitis B e antigen (HBeAg), who received a 104-week lamivudine and adefovir dipivoxil combination therapy. The mutations within the CP/preC were analyzed against genotype specific reference sequences...
January 11, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28079918/dose-evaluation-of-lamivudine-in-hiv-infected-children-aged-5%C3%A2-months-18%C3%A2-years-based-on-a-population-pharmacokinetic-analysis
#6
Esther J H Janssen, Diane E T Bastiaans, Pyry A J Välitalo, Annemarie M C van Rossum, Evelyne Jacqz-Aigrain, Hermione Lyall, Catherijne A J Knibbe, David M Burger
AIM: The objectives of this study were to characterise age-related changes in lamivudine pharmacokinetics in children and evaluate lamivudine exposure, followed by dose recommendations for subgroups in which target steady state AUC0-24h is not reached. METHODS: Population pharmacokinetic modelling was performed in NONMEM using data from two model building datasets and two external datasets (n = 180 (age 0.4-18 years, bodyweight 3.4-60.5 kg); 2,061 samples (median 12 per child); daily oral dose 60-300 mg (3...
January 12, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28079295/hypophosphatemia-predicts-a-failure-to-recover-from-adefovir-related-renal-injury-after-dose-reduction-in-lamivudine-resistant-hepatitis-b-patients
#7
Tatsuo Yamamoto, Yasuhiko Maruyama, Naro Ohashi, Hideo Yasuda, Masami Shinozaki
AIM: In chronic hepatitis B patients receiving 10 mg adefovir, dose reduction is recommended when renal injury appears. However, recovery is not always achieved and markers that recommend switching to another antiviral agent are unknown. We investigated adefovir-related renal injury, recovery after dose reduction, and their predictors. METHODS: The renal injury in 77 chronic hepatitis B patients receiving 10 mg adefovir and recovery after dose reduction to alternate day administration in those with adefovir-related renal injury were assessed...
January 12, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28072494/hepatitis-b-virus-reactivation-in-breast-cancer-patients-undergoing-chemotherapy-a-review-and-meta-analysis-of-prophylaxis-management
#8
Zihao Liu, Lei Jiang, Gehao Liang, Erwei Song, Yubao Zheng, Chang Gong
BACKGROUND & AIMS: Hepatitis B virus (HBV) reactivation during or after chemotherapy in breast cancer patients has become a remarkable clinical problem. Prophylactic nucleos(t)ide analogues (NAs) are recommended for breast cancer patients who are hepatitis B surface antigen (HBsAg) positive before chemotherapy. We performed an up-to-date meta-analysis to compare the efficacy of prophylactic lamivudine use with non-prophylaxis in HBsAg positive breast cancer patients undergoing chemotherapy...
January 10, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28067752/efficacy-and-safety-of-lamivudine-versus-entecavir-for-treating-chronic-hepatitis-b-virus-related-acute-exacerbation-and-acute-on-chronic-liver-failure-a-systematic-review-and-meta-analysis
#9
Kuang-Wei Huang, Ka-Wai Tam, Jiing-Chyuan Luo, Yi-Chun Kuan
BACKGROUND: Oral nucleos(t)ide analogs are recommended for patients with chronic hepatitis B virus (HBV)-related acute exacerbation (AE) and acute-on-chronic liver failure (ACLF). The efficacy and safety of administering entecavir (ETV) and lamivudine (LAM) to such patients remain unclear. METHODS: A comprehensive literature search was performed to select studies published before December 2015 on therapy involving ETV or LAM for chronic HBV-related AE with or without ACLF...
August 30, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28065890/impact-of-obesity-on-antiretroviral-pharmacokinetics-and-immuno-virological-response-in-hiv-infected-patients-a-case-control-study
#10
Vincent Madelain, Minh P Le, Karen Champenois, Charlotte Charpentier, Roland Landman, Veronique Joly, Patrick Yeni, Diane Descamps, Yazdan Yazdanpanah, Gilles Peytavin
BACKGROUND: Obesity has high prevalence among HIV-infected patients. Increased adipose tissue mass affects the pharmacokinetics of numerous drugs, but few data are available for antiretroviral drugs. OBJECTIVES: In this study we aimed to explore the pharmacokinetics of antiretroviral drugs and the immuno-virological response in obese patients with HIV infection. PATIENTS AND METHODS: We examined data from 2009 to 2012 in our hospital's database for HIV-1-infected patients who received an antiretroviral drug (abacavir, emtricitabine, lamivudine, tenofovir, efavirenz, etravirine, nevirapine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir or raltegravir)...
January 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28063964/impact-of-hepatitis-b-core-antibody-hbcab-seropositivity-on-the-outcome-of-autologous-hematopoietic-stem-cell-transplantation-for-multiple-myeloma
#11
Ankur Varma, Laura Biritxinaga, Rima M Saliba, Maximilian Stich, Sarah Francesca Jauch, Aimaz Afrough, Medhavi Honhar, Uday R Popat, Mehnaz A Shafi, Nina Shah, Qaiser Bashir, Yvonne Dinh, Chitra Hosing, Richard E Champlin, Muzaffar H Qazilbash
Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (controls) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen...
January 4, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28060017/determinants-of-virological-outcome-and-adverse-events-in-african-children-treated-with-paediatric-nevirapine-fixed-dose-combination-tablets
#12
Andrzej Bienczak, Paolo Denti, Adrian Cook, Lubbe Wiesner, Veronica Mulenga, Cissy Kityo, Addy Kekitiinwa, Diana M Gibb, David Burger, A Sarah Walker, Helen Mcilleron
BACKGROUND: Nevirapine is the only non-nucleoside reverse transcriptase inhibitor currently available as a paediatric fixed-dose combination tablet and is widely used in African children. Nonetheless, the number of investigations into pharmacokinetic determinants of virological suppression in African children is limited and the predictive power of the current therapeutic range was never evaluated in this population, thereby limiting treatment optimisation. METHODS: We analysed data from 322 African children (aged 0...
January 4, 2017: AIDS
https://www.readbyqxmd.com/read/28035758/genotypic-tropism-testing-of-proviral-dna-to-guide-maraviroc-initiation-in-aviraemic-subjects-48-week-analysis-of-results-from-the-protest-study
#13
E Poveda, J Hernández-Quero, M J Pérez-Elías, M A Ribas, O J Martínez-Madrid, J Flores, J Navarro, F Gutiérrez, M García-Deltoro, A Imaz, A Ocampo, A Artero, F Blanco, E Bernal, J Pasquau, C Mínguez-Gallego, N Pérez, A Aiestaran, F García, R Paredes
OBJECTIVES: Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. METHODS: PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with HIV-1 RNA < 50 copies/mL on stable ART during the previous 6 months who required an ART change because of toxicity and who had R5 HIV, as determined by proviral DNA genotypic tropism testing, initiated MVC with two nucleoside reverse transcriptase inhibitors (NRTIs) and were followed for 48 weeks...
December 30, 2016: HIV Medicine
https://www.readbyqxmd.com/read/28028587/safety-of-zidovudine-lamivudine-scored-tablets-in-children-with-hiv-infection-in-europe-and-thailand
#14
Ali Judd
BACKGROUND: Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) network. METHODS: Fourteen cohorts provided data on patients <18 years of age taking ZDV/3TC scored tablets between 2008 and 2012...
December 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28027284/antiretroviral-treatment-initiated-in-the-first-month-of-life
#15
Lisa Frigati, Elke Wynberg, Jean Maritz, Sandi Holgate, Mark F Cotton, Helena Rabie
BACKGROUND: Earlier diagnosis of HIV-infected infants facilitates earlier access to therapy and improved clinical outcomes. AIM: The aim of this study was describe the management of infants who started antiretroviral therapy in the first month of life. METHODS: A retrospective review was performed on HIV-infected neonates who started ART within the first month of life between January 2013 and March 2015. RESULTS: 997 neonates had one HIV PCR test...
December 23, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28025872/lamivudine-therapy-during-the-second-vs-the-third-trimester-for-preventing-transmission-of-chronic-hepatitis-b
#16
C Q Pan, W Yi, M Liu, G Wan, Y-H Hu, M-F Zhou
There are little data on the timing of initiating lamivudine therapy for preventing transmission of hepatitis B in highly viremic mothers. Between May 2008 and January 2015, we retrospectively enrolled mothers with HBV DNA >6 log10  copies/mL who received lamivudine during pregnancy, and we compared them to untreated mothers. The primary measurement was the vertical transmission rate. The secondary outcomes were the mothers' and infants' safety. Among 249 consecutive mothers enrolled, 66 and 94 received lamivudine during the second and third trimesters, respectively, and 89 were untreated...
December 26, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28017761/tenofovir-alafenamide-demonstrates-broad-cross-genotype-activity-against-wild-type-hbv-clinical-isolates-and-maintains-susceptibility-to-drug-resistant-hbv-isolates-in%C3%A2-vitro
#17
Yang Liu, Michael D Miller, Kathryn M Kitrinos
Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV). This study evaluated the antiviral activity of TAF against wild-type genotype A-H HBV clinical isolates as well as adefovir-resistant, lamivudine-resistant, and entecavir-resistant HBV isolates. Full length HBV genomes or the polymerase/reverse transcriptase (pol/RT) region from treatment-naïve patients infected with HBV genotypes A-H were amplified and cloned into an expression vector under the control of a CMV promoter. In addition, 11 drug resistant HBV constructs were created by site-directed mutagenesis of a full length genotype D construct...
December 23, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28017149/htlv-1-associated-neurological-disorders
#18
Muhammad Yasir Khan, Ishaq Nasib Khan, Muhammad Farman, Saleh Al Karim, Ishtiaq Qadri, Muhammad Amjad Kamal, Khalid Al Ghamdi, Steve Harakeh
Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus which is endemic to certain regions of the world and infects around 10-20 million people. HTLV-1 is the etiologic agent of Adult T cell leukemia/lymphoma and HTLV-1 associated neurological disorders including mainly HTLV-1 associated myelopathy/Tropical spastic paraparesis. The involvement of the central nervous diseases occurs among: HTLV-1 infected patients from endemic areas, HIV positive individuals and drug users. The ability of HTLV-1 to cause associated neuropathies starts with the virus crossing the blood brain barrier (BBB), then entering and infecting the cells of the central nervous system...
December 22, 2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/28011962/tenofovir-disoproxil-fumarate-monotherapy-maintains-hbv-suppression-achieved-by-a-de-novo-combination-of-lamivudine-adefovir-a-pilot-study
#19
Giuseppe Ruggiero, Aldo Marrone, Ilaria Rainone, Adriana Boemio, Luigi Elio Adinolfi, Giuseppe Pasquale, Luca Rinaldi, Barbara Guerrera, Lorenzo Andreana, Rosa Zampino
Chronic hepatitis B (CHB) treatment aims at long-term suppression of HBV replication and improvement in clinical outcomes. We describe the data of a pilot, non-profit study in which patients with CHB were treated with de novo combination lamivudine-adefovir (LAM-ADV) for at least four years with a view to HBV suppression and resistance prevention, and shifted to tenofovir (TDF) when new antiviral agents were available. Fifty-one HBeAg negative patients were enrolled. Histology was available for 39 patients and data of liver stiffness (LS) for 24 patients at baseline...
1, 2016: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/28008867/dolutegravir-plasma-concentrations-according-to-companion-antiretroviral-drug-unwanted-drug-interaction-or-desirable-boosting-effect
#20
Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni
BACKGROUND: Studies in healthy volunteers have shown that the recently approved HIV integrase inhibitor dolutegravir has limited drug-to-drug interaction profile. Here we carried out a pharmacokinetic survey in HIV-infected patients given dolutegravir as part of their antiretroviral therapy. METHODS: Dolutegravir plasma trough concentrations were measured in 78 HIV infected patients given the drug in combination with a protease inhibitor, a non nucleoside reverse transcriptase inhibitor or abacavir/lamivudine...
December 23, 2016: Antiviral Therapy
keyword
keyword
114587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"